Surgical Endoscopy

, Volume 24, Issue 2, pp 283–289 | Cite as

Minimally invasive colon resection for malignant colonic conditions is associated with a transient early increase in plasma sVEGFR1 and a decrease in sVEGFR2 levels after surgery

  • H. M. C. Shantha Kumara
  • J. C. Cabot
  • A. Hoffman
  • M. Luchtefeld
  • M. F. Kalady
  • N. Hyman
  • D. Feingold
  • R. Baxter
  • R. L. WhelanEmail author



Plasma VEGF levels increase after minimally invasive colorectal resection (MICR) and remain elevated for 2–4 weeks. VEGF induces physiologic and pathologic angiogenesis by binding to endothelial cell (EC) bound VEGF-Receptor-1 (VEGFR1) and VEGFR2. Soluble forms of these receptors sequester plasma VEGF, decreasing the amount available to bind to EC-bound receptors. Ramifications of surgery-related plasma VEGF changes partially depend on plasma levels of sVEGFR1 and sVEGFR2. This study assessed perioperative sVEGFR1 and sVEGFR2 levels after MICR in patients with colorectal cancer.


Forty-five patients were studied; blood samples were taken from all patients preoperatively (preop) and on postoperative days (POD) 1 and 3; in most a fourth sample was drawn between POD 7–30. Late samples were bundled into two time points: POD 7–13 and POD 14–30. sVEGFR1 and sVEGFR2 levels were measured via ELISA. sVEGFR2 data are reported as mean ± SD and were assessed with the paired samples t test. sVEGFR1 data were not normally distributed. They are reported as median and 95% confidence interval (CI) and were assessed with the Wilcoxon signed-Rank test (p < 0.05).


Preoperatively, the mean plasma sVEGFR2 level (7583.9 pg/ml) was greater than the sVEGFR1 result (98.3 pg/ml). Compared with preop levels, sVEGFR2 levels were significantly lower on POD 1 (6068.2 pg/ml, ±2034.5) and POD 3 (6227.6 pg/ml, ±2007.0), whereas sVEGFR1 levels were significantly greater on POD 1 (237.5 pg/ml; 95% CI, 89.6–103.5), POD 3 (200.2 pg/ml; 95% CI, 159–253), and POD 7−13 (102.9 pg/ml; 95% CI, 189.7–253). No differences were found on POD 7–13 for sVEGFR2 or POD 14–30 for either protein.


sVEGFR2 values decreased and sVEGFR1 levels increased early after MICR; sVEGFR2 changes dominate due to their much larger magnitude. The net result is less plasma VEGF bound by soluble receptors and more plasma VEGF available to bind to ECs early after surgery.


sVEGFR1 sVEGFR2 Colon cancer Colorectal resection Surgery-related plasma alterations 


  1. 1.
    Kirman I, Belizon A, Balik E, Feingold D, Arnell T, Horst P, Kumara S, Cekic V, Jain S, Nasar A, Whelan RL (2007) Perioperative sargramostim (recombinant human GM-CSF) induces an increase in the level of soluble VEGFR1 in colon cancer patients undergoing minimally invasive surgery. Eur J Surg Oncol 33:1169–1176PubMedGoogle Scholar
  2. 2.
    Mels AK, Statius Muller MG, van Leeuwen PA, von Blomberg BM, Scheper RJ, Cuesta MA, Beelen RH, Meijer S (2001) Immune-stimulating effects of low-dose perioperative recombinant granulocyte-macrophage colony-stimulating factor in patients operated on for primary colorectal carcinoma. Br J Surg 88:539–544CrossRefPubMedGoogle Scholar
  3. 3.
    Shantha Kumara HMC, Kirman I, Feingold D, Cekic V, Nasar A, Arnell T, Balik E, Hoffman A, Baxter R, Conte S, Whelan RL (2008) Perioperative GMCSF limits the proangiogenic plasma protein changes associated with colorectal cancer resection. Eur J Surg Oncol 35:295–301PubMedGoogle Scholar
  4. 4.
    Allendorf JD, Bessler M, Horvath KD, Marvin MR, Laird DA, Whelan RL (1998) Increased tumor establishment and growth after open vs laparoscopic bowel resection in mice. Surg Endosc 12:1035–1038CrossRefPubMedGoogle Scholar
  5. 5.
    Carter JJ, Feingold DL, Kirman I, Oh A, Wildbrett P, Asi Z, Fowler R, Huang E, Whelan RL (2003) Laparoscopic-assisted cecectomy is associated with decreased formation of postoperative pulmonary metastases compared with open cecectomy in a murine model. Surgery 134:432–436CrossRefPubMedGoogle Scholar
  6. 6.
    Belizon A, Balik E, Horst P, Feingold D, Arnell T, Azarani T, Cekic V, Skitt R, Kumara S, Whelan RL (2008) Persistent elevation of plasma vascular endothelial growth factor levels during the first month after minimally invasive colorectal resection. Surg Endosc 22:287–297CrossRefPubMedGoogle Scholar
  7. 7.
    Shantha Kumara HMC, Hoffman A, Kim IY, Feingold D, Dujovny N, Kallady M, Luchtefeld M, Whelan RL (2009) Colorectal resection, both open and laparoscopic- assisted, in patients with benign indications is associated with proangiogenic changes in plasma angiopoietin 1 and 2 levels. Surg Endosc 23:409–415CrossRefPubMedGoogle Scholar
  8. 8.
    Ferrara N, Davis-Smyth T (1997) The biology of vascular endothelial growth factor. Endocr Rev 18:4–25CrossRefPubMedGoogle Scholar
  9. 9.
    Hanahan D, Folkman J (1996) Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86:353–364CrossRefPubMedGoogle Scholar
  10. 10.
    Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z (1999) Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 13:9–22PubMedGoogle Scholar
  11. 11.
    Hicklin DJ, Ellis LM (2005) Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 23:1011–1027CrossRefPubMedGoogle Scholar
  12. 12.
    Bellamy WT, Richter L, Frutiger Y, Grogan TM (1999) Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies. Cancer Res 59:728–733PubMedGoogle Scholar
  13. 13.
    Decaussin M, Sartelet H, Robert C, Moro D, Claraz C, Brambilla C, Brambilla E (1999) Expression of vascular endothelial growth factor (VEGF) and its two receptors (VEGF-R1-Flt1 and VEGF-R2-Flk1/KDR) in non-small cell lung carcinomas (NSCLCs): correlation with angiogenesis and survival. J Pathol 188:369–377CrossRefPubMedGoogle Scholar
  14. 14.
    Ferrer FA, Miller LJ, Lindquist R, Kowalczyk P, Laudone VP, Albertsen PC, Kreutzer DL (1999) Expression of vascular endothelial growth factor receptors in human prostate cancer. Urology 54:567–572CrossRefPubMedGoogle Scholar
  15. 15.
    Folkman J (1997) Addressing tumor blood vessels. Nat Biotechnol 15:510CrossRefPubMedGoogle Scholar
  16. 16.
    Lacal PM, Failla CM, Pagani E, Odorisio T, Schietroma C, Falcinelli S, Zambruno G, D’Atri S (2000) Human melanoma cells secrete and respond to placenta growth factor and vascular endothelial growth factor. J Invest Dermatol 115:1000–1007CrossRefPubMedGoogle Scholar
  17. 17.
    Price DJ, Miralem T, Jiang S, Steinberg R, Avraham H (2001) Role of vascular endothelial growth factor in the stimulation of cellular invasion and signaling of breast cancer cells. Cell Growth Differ 2:129–135Google Scholar
  18. 18.
    George DJ, Halabi S, Shepard TF, Vogelzang NJ, Hayes DF, Small EJ, Kantoff PW (2001) Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480. Clin Cancer Res 7:1932–1936PubMedGoogle Scholar
  19. 19.
    Hyodo I, Doi T, Endo H, Hosokawa Y, Nishikawa Y, Tanimizu M, Jinno K, Kotani Y (1998) Clinical significance of plasma vascular endothelial growth factor in gastrointestinal cancer. Eur J Cancer 34:2041–2045CrossRefPubMedGoogle Scholar
  20. 20.
    Karayiannakis AJ, Syrigos KN, Polychronidis A, Zbar A, Kouraklis G, Simopoulos C, Karatzas G (2002) Circulating VEGF levels in the serum of gastric cancer patients: correlation with pathological variables, patient survival, and tumor surgery. Ann Surg 236:37–42CrossRefPubMedGoogle Scholar
  21. 21.
    Karayiannakis AJ, Syrigos KN, Zbar A, Baibas N, Polychronidis A, Simopoulos C, Karatzas G (2002) Clinical significance of preoperative serum vascular endothelial growth factor levels in patients with colorectal cancer and the effect of tumor surgery. Surgery 131:548–555CrossRefPubMedGoogle Scholar
  22. 22.
    Takeda A, Shimada H, Imaseki H, Okazumi S, Natsume T, Suzuki T, Ochiai T (2000) Clinical significance of serum vascular endothelial growth factor in colorectal cancer patients: correlation with clinicopathological factors and tumor markers. Oncol Rep 7:333–338PubMedGoogle Scholar
  23. 23.
    De Vita F, Orditura M, Lieto E, Infusino S, Morgillo F, Martinelli E, Castellano P, Romano C, Ciardiello F, Catalano G, Pignatelli C, Galizia G (2004) Elevated perioperative serum vascular endothelial growth factor levels in patients with colon carcinoma. Cancer 100:270–278CrossRefPubMedGoogle Scholar
  24. 24.
    Hormbrey E, Han C, Roberts A, McGrouther DA, Harris AL (2003) The relationship of human wound vascular endothelial growth factor (VEGF) after breast cancer surgery to circulating VEGF and angiogenesis. Clin Cancer Res 9:4332–4339PubMedGoogle Scholar
  25. 25.
    Karayiannakis AJ, Zbar A, Polychronidis A, Simopoulos C (2003) Serum and drainage fluid vascular endothelial growth factor levels in early surgical wounds. Eur Surg Res 35:492–496CrossRefPubMedGoogle Scholar
  26. 26.
    Belizon A, Balik E, Feingold DL, Bessler M, Arnell TD, Forde KA, Horst PK, Jain S, Cekic V, Kirman I, Whelan RL (2006) Major abdominal surgery increases plasma levels of vascular endothelial growth factor: open more so than minimally invasive methods. Ann Surg 244:792–798CrossRefPubMedGoogle Scholar
  27. 27.
    Wu FP, Westphal JR, Hoekman K, Mels AK, Statius Muller MG, de Waal RW, Beelen RH, van Leeuwen PA, Meijer S, Cuesta MA (2004) The effects of surgery, with or without rhGM-CSF, on the angiogenic profile of patients treated for colorectal carcinoma. Cytokine 25:68–72CrossRefPubMedGoogle Scholar
  28. 28.
    Matsumoto T, Claesson-Welsh L (2001) VEGF receptor signal transduction. Sci STKE 2001 112:RE21Google Scholar
  29. 29.
    Ferrara N, Gerber HP, LeCouter J (2003) The biology of VEGF and its receptors. Nat Med 9:669–676CrossRefPubMedGoogle Scholar
  30. 30.
    Jain RK (1994) Barriers to drug delivery in solid tumors. Sci Am 271:58–65CrossRefPubMedGoogle Scholar
  31. 31.
    Dias S, Hattori K, Heissig B, Zhu Z, Wu Y, Witte L, Hicklin DJ, Tateno M, Bohlen P, Moore MA, Rafii S (2001) Inhibition of both paracrine and autocrine VEGF/ VEGFR-2 signaling pathways is essential to induce long-term remission of xenotransplanted human leukemias. Proc Natl Acad Sci U S A 98:10857–10862CrossRefPubMedGoogle Scholar
  32. 32.
    Dias S, Hattori K, Zhu Z, Heissig B, Choy M, Lane W, Wu Y, Chadburn A, Hyjek E, Gill M, Hicklin DJ, Witte L, Moore MA, Rafii S (2000) Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration. J Clin Invest 106:511–521CrossRefPubMedGoogle Scholar
  33. 33.
    Fan F, Wey JS, McCarty MF, Belcheva A, Liu W, Bauer TW, Somcio RJ, Wu Y, Hooper A, Hicklin DJ, Ellis LM (2005) Expression and function of vascular endothelial growth factor receptor-1 on human colorectal cancer cells. Oncogene 24:2647–2653CrossRefPubMedGoogle Scholar
  34. 34.
    Hayashibara T, Yamada Y, Miyanishi T, Mori H, Joh T, Maeda T, Mori N, Maita T, Kamihira S, Tomonaga M (2001) Vascular endothelial growth factor and cellular chemotaxis: a possible autocrine pathway in adult T-cell leukemia cell invasion. Clin Cancer Res 7:2719–2726PubMedGoogle Scholar
  35. 35.
    Lamszus K, Ulbricht U, Matschke J, Brockmann MA, Fillbrandt R, Westphal M (2003) Levels of soluble vascular endothelial growth factor (VEGF) receptor 1 in astrocytic tumors and its relation to malignancy, vascularity, and VEGF-A. Clin Cancer Res 9:1399–1405PubMedGoogle Scholar
  36. 36.
    Toi M, Bando H, Ogawa T, Muta M, Hornig C, Weich HA (2002) Significance of vascular endothelial growth factor (VEGF)/soluble VEGF receptor-1 relationship in breast cancer. Int J Cancer 98:14–18CrossRefPubMedGoogle Scholar
  37. 37.
    Yamaguchi T, Bando H, Mori T, Takahashi K, Matsumoto H, Yasutome M, Weich H, Toi M (2007) Over expression of soluble vascular endothelial growth factor receptor 1 in colorectal cancer: Association with progression and prognosis. Cancer Sci 98:405–410CrossRefPubMedGoogle Scholar
  38. 38.
    Aref S, Sakrana M, Hafez AA, Hamdy M (2005) Soluble VEGF/sFLt1 ratio is an independent predictor of AML patient out come. Hematology 10:131–134CrossRefPubMedGoogle Scholar
  39. 39.
    Ilhan N, Deveci F (2004) Functional significance of vascular endothelial growth factor and its receptor (receptor-1) in various lung cancer types. Clin Biochem 37:840–845CrossRefPubMedGoogle Scholar
  40. 40.
    Kumar H, Heer K, Greenman J, Kerin MJ, Monson JR (2002) Soluble FLT-1 is detectable in the sera of colorectal and breast cancer patients. Anticancer Res 22:1877–1880PubMedGoogle Scholar
  41. 41.
    Taoka T, Iwasaki S, Uchida H, Fukusumi A, Kichikawa K, Nakagawa H, Takayama K, Sakamoto M, Ohishi H (2000) Suppression of tumor angiogenesis and growth by gene transfer of a soluble form of vascular endothelial growth factor receptor into a remote organ. Cancer Res 60:2169–2177Google Scholar
  42. 42.
    Hu Q, Dey AL, Yang Y, Shen Y, Jilani IB, Estey EH, Kantarjian HM, Giles FJ, Albitar M (2004) Soluble vascular endothelial growth factor receptor 1, and not receptor 2, is an independent prognostic factor in acute myeloid leukemia and myelodysplastic syndromes. Cancer 100:1884–1891CrossRefPubMedGoogle Scholar
  43. 43.
    Jain RK, Duda DG, Clark JW, Loeffler JS (2006) Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 3:24–40CrossRefPubMedGoogle Scholar
  44. 44.
    Shantha Kumara HMC, Cabot CJ, Hoffman A, Luchtefeld M, Kalady M, Hyman N, Feingold D, Baxter R, Whelan RL (2009) Minimally invasive colon resection is associated with a transient early increase in plasma sVEGFR1 and a decrease in sVEGFR2 levels after surgery. Surg Endosc [Epub ahead of print]Google Scholar
  45. 45.
    Gill M, Dias S, Hattori K, Rivera ML, Hicklin D, Witte L, Girardi L, Yurt R, Himel H, Rafii S (2001) Vascular trauma induces rapid but transient mobilization of VEGFR2(+)AC133(+) endothelial precursor cells. Circ Res 88:167–174PubMedGoogle Scholar
  46. 46.
    Kitsukawa T, Shimono A, Kawakami A, Kondoh H, Fujisawa H (1995) Overexpression of a membrane protein, neuropilin, in chimeric mice causes anomalies in the cardiovascular system, nervous system and limbs. Development 121:4309–4318PubMedGoogle Scholar
  47. 47.
    Miao HQ, Lee P, Lin H, Soker S, Klagsbrun M (2000) Neuropilin-1 expression by tumor cells promotes tumor angiogenesis and progression. FASEB J 14:2532–2539CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  • H. M. C. Shantha Kumara
    • 1
  • J. C. Cabot
    • 1
  • A. Hoffman
    • 1
  • M. Luchtefeld
    • 2
  • M. F. Kalady
    • 3
  • N. Hyman
    • 4
  • D. Feingold
    • 1
  • R. Baxter
    • 1
  • R. L. Whelan
    • 1
    Email author
  1. 1.Section of Colon and Rectal Surgery, Department of SurgeryNew York-Presbyterian Hospital-Columbia CampusNew YorkUSA
  2. 2.Division of Colon and Rectal SurgeryFerguson ClinicGrand RapidsUSA
  3. 3.Department of Colorectal SurgeryCleveland ClinicClevelandUSA
  4. 4.Department of Surgery, Fletcher 465University of Vermont, College of MedicineBurlingtonUSA

Personalised recommendations